CERNER MILLENNIUM POWERORDERS AND MED PROFILE
Report
- Report Number
- 1931259-2008-00004
- Event Type
- Malfunction
- Date Received
- May 23, 2008
- Date of Event
- April 23, 2008
- Report Date
- May 23, 2008
- Manufacturer
- CERNER CORP.
- Product Code
- LNX
- PMA / PMN Number
- NA
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- MO, US
- Reporter Occupation
- OTHER
Narratives
CERNER HAS DISTRIBUTED A PRIORITY REVIEW FLASH NOTIFICATION MAY 23, 2008 TO ALL POTENTIALLY IMPACTED CLIENTS SITES. THE NOTIFICATION INCLUDES A DESCRIPTION OF THE ISSUE AND AN INTERIM WORKFLOW ADJUSTMENT TO PREVENT THE MALFUNCTION. USER DOCUMENTATION IS BEING UPDATED TO ADDRESS THE ISSUE FOR ALL SITES THAT COULD BE POTENTIALLY IMPACTED. CERNER CORPORATION WILL PROVIDE A FOLLOW-UP REPORT WHEN THE DOCUMENTATION IS AVAILABLE.
THE ISSUE INVOLVES THE ORDER ENTRY FORMATS IN POWERORDERS AND AFFECTS SITES THAT USE POWERORDERS AND MEDICATION PROFILE. WHEN CREATING THE VOLUME DOSE DETAIL IN THE ORDER ENTRY FORMATS (OEF), THE STRENGTH ORDER FORMATS REQUIRE THE VOLUME DOSE TO HAVE AN "=" SIGN AS A PREFIX LABEL. FAILURE TO ADHERE TO THIS BUILD CAN RESULT IN AN INPATIENT PRESCRIPTION ORDER CONVERTED TO PRODUCE AN OUTPATIENT PRESCRIPTION THAT MAY BE MISLEADING. THIS ONLY OCCURS WHEN THE INPATIENT ORDER USED IS VERIFIED WITH A PHARMACY PRODUCT AND THE FORMULATION USED DOES NOT EXACTLY MATCH THE DOSE. A FORMULATION FACTOR OF MORE OR LESS THAN ONE IS USED TO ACHIEVE THE VOLUME AND THE ORDER IS THEN CONVERTED TO A PRESCRIPTION. FOR EXAMPLE, 500 MG = 1 TAB OR 250 MG TIMES 2 TABS = 500 MG. PATIENT CARE COULD BE ADVERSELY AFFECTED, AS A PATIENT COULD RECEIVE EITHER MORE OR LESS OF A MEDICATION THERAPY THAN INTENDED. CERNER HAS RECEIVED COMMUNICATION OF ORDER DISCREPANCIES DISCOVERED DURING A CHART REVIEW AS A RESULT OF THIS ISSUE.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1 | CERNER MILLENNIUM POWERORDERS AND MED PROFILE | SOFTWARE | LNX | CERNER CORP. | 2001 THROUGH 2007 | NA |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 |